Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21282546 | 0.86 | CCKBR (0.39) | CCKBRPAX8EPHX2BCHEHRH2 | |
| SCHEMBL23758472 | 0.82 | CCKBR (0.37) | CCKBRBCHEHRH2OPRM1HTR2B | |
| SCHEMBL13142140 | 0.81 | CCKBR (0.36) | CCKBREPHX2BCHEHRH2OPRM1 | |
| SCHEMBL24202026 | 0.80 | CCKBR (0.38) | CCKBREPHX2BCHEHRH2OPRM1 | |
| SCHEMBL16684897 | 0.79 | CCKBR (0.39) | CCKBRPAX8BCHEHRH2OPRM1 | |
| SCHEMBL20505538 | 0.78 | TACR2 (0.38) | — | |
| SCHEMBL1118519 | 0.77 | CCKBR (0.42) | CCKBRPAX8BCHEHRH2OPRM1 | |
| SCHEMBL12013752 | 0.77 | CCKBR (0.42) | CCKBRPAX8BCHEHRH2OPRM1 | |
| SCHEMBL12141050 | 0.77 | CCKBR (0.42) | CCKBRPAX8BCHEHRH2OPRM1 | |
| SCHEMBL550107 | 0.77 | CCKBR (0.42) | CCKBRPAX8HRH2OPRM1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939981-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2024-04-03 | — | — | EP | disclosed |
| CN-108495855-B | Fused thiazolopyrimidine derivatives as MNK inhibitors | 生命弧度公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3939981-A1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LifeArc (GB) | 2022-01-19 | — | — | EP | disclosed |
| EP-3939981-A1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LifeArc (GB) | 2022-01-19 | — | — | EP | disclosed |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | LIFEARC (GB) | 2021-10-05 | — | — | US | disclosed |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | LIFEARC (GB) | 2021-10-05 | — | — | US | disclosed |
| EP-3377501-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2021-08-18 | — | — | EP | disclosed |
| EP-3377501-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2021-08-18 | — | — | EP | disclosed |
| US-20200247822-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | ASTRAZENECA UK LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-20200247822-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | ASTRAZENECA UK LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-10669284-B2 | Fused thiazolopyrimidine derivatives as MNKS inhibitors | LIFEARC (GB) | 2020-06-02 | — | — | US | disclosed |
| US-10669284-B2 | Fused thiazolopyrimidine derivatives as MNKS inhibitors | LIFEARC (GB) | 2020-06-02 | — | — | US | disclosed |
| US-20180346483-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | LIFEARC (GB) | 2018-12-06 | — | — | US | disclosed |
| EP-3377501-A1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LifeArc (GB) | 2018-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346483-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | MAPT, TTBK1, TTBK2 | CCKBR 3777/4885IDO1 2599/4885PAX8 4063/4885 |
| US-20200247822-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | MAPT, TTBK1, TTBK2 | CCKBR 3759/4885IDO1 2627/4885PAX8 4042/4885 |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | MAPT, TTBK1, TTBK2 | CCKBR 3759/4885IDO1 2627/4885PAX8 4042/4885 |
| US-10669284-B2 | Fused thiazolopyrimidine derivatives as MNKS inhibitors | MAPT, TTBK1, TTBK2 | CCKBR 3777/4885IDO1 2599/4885PAX8 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.